Second generation tyrosine kinase inhibitors prevent disease progression in high-risk (high CIP2A) chronic myeloid leukaemia patients
2010 ◽
Vol 150
(3)
◽
pp. 303-312
◽
2017 ◽
Vol 182
(3)
◽
pp. 427-429
◽
2019 ◽
Vol 6
(8)
◽
pp. e398-e408
◽
2015 ◽
Vol 174
(2)
◽
pp. 456-458
◽